| Urbanise.Com Limited (UBN) ORDINARY FULLY PAID |
Information Technology |
$57 |
Investor Presentation
|
28 Feb 2025 8:59AM |
$0.510 |
$0.720 |
risen by
41.18%
|
|
UBN - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY2025 receipts of $7,761k were $583k lower vs pcp.
- Payments to suppliers and employees reduced by $2,198k due to cost reduction initiatives.
- Average monthly cash generated for H1 FY2025 was $139k.
- H1 FY2025 total revenue was $6,305k, a slight increase from H1 FY2024.
- Operating expenses decreased by 13.4% to $6,382k.
- Net loss reduced by 41.2% to $896k.
- Urbanise aims to achieve cash flow breakeven in FY2025.
- Contracted ARR decreased by 2% vs pcp.
- ARR retention rate was reported at 87.3%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iron Road Limited (IRD) ORDINARY FULLY PAID |
Materials |
$18 |
Update - Notification of buy-back - IRD
|
28 Feb 2025 8:59AM |
$0.055 |
$0.022 |
fallen by
60%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$585 |
Update - Notification of buy-back - FPR
|
28 Feb 2025 8:58AM |
$2.550 |
$2.710 |
risen by
6.27%
|
|
| Clean Seas Seafood Limited (CSS) ORDINARY FULLY PAID |
Consumer Staple |
- |
Half Yearly Report and Accounts
|
28 Feb 2025 8:58AM |
$0.135 |
$0.135 |
fallen by
0%
|
|
CSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue down 10.4% to $30.5 million
- Realised price up 3% to $23.24/kg
- FV loss on biological assets of $14.1 million due to poor performance of the Year Class 24 cohort
- Impairment of $14.0 million recognised
- Statutory net loss of $32.6 million
- Operating cash flows of $5.7 million, up $8.4 million
- Free cash flows of $4.3 million, up $9.9 million
- Total assets reduced from $87.0 million to $49.5 million
- Total liabilities reduced from $25.0 million to $20.1 million
- Continuing efforts to assess merger proposal with Yumbah Aquaculture Ltd
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Australia Limited (FGX) ORDINARY FULLY PAID |
Financials |
$588 |
Dividend/Distribution - FGX
|
28 Feb 2025 8:58AM |
$1.270 |
$1.430 |
risen by
12.60%
|
|
FGX - Price-sensitive ASX Announcement
Full Release
Key Points
- Entity name: FUTURE GENERATION AUSTRALIA LIMITED
- Security on which the Distribution will be paid: FGX - ORDINARY FULLY PAID
- Announcement Type: New announcement
- Distribution Amount: AUD 0.03500000
- Ex Date: 8/5/2025
- Record Date: 9/5/2025
- Payment Date: 21/5/2025
- DRP election date: Tuesday May 13, 2025 17:00:00
- Type of dividend/distribution: relates to a period of six months
- The dividend relates to the financial reporting period ending 31/12/2024
- The ordinary dividend/distribution is fully franked at 100%
- DRP Status: Full DRP
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Centrex Limited (CXM) ORDINARY FULLY PAID |
Materials |
- |
Update - Proposed issue of securities - CXM
|
28 Feb 2025 8:58AM |
$0.017 |
$0.017 |
fallen by
0%
|
|
| Centrex Limited (CXM) ORDINARY FULLY PAID |
Materials |
- |
Entitlement Offer - Extension of Closing Date
|
28 Feb 2025 8:58AM |
$0.017 |
$0.017 |
fallen by
0%
|
|
| Frontier Digital Ventures Limited (FDV) ORDINARY FULLY PAID |
Communication Services |
$118 |
Appendix 4E and Audited Financial Statements
|
28 Feb 2025 8:57AM |
$0.230 |
$0.270 |
risen by
17.39%
|
|
FDV - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated revenue of A$68.1 million in FY24, a 2% increase from FY23.
- Group reported a loss of A$11.1 million, higher than the prior year.
- EBITDA decreased by 52%, impacted by rising operational costs.
- The board confirms the company's ability to meet financial obligations.
- Future strategies include enhancing product offerings and operational efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$112 |
Bubs Australia - Half Year Results Commentary
|
28 Feb 2025 8:56AM |
$0.145 |
$0.125 |
fallen by
13.79%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- 1HY25 net profit after tax of $3.6m, up from a net loss of $(7.7)m in 1HY24
- 1HY25 revenue was $48.5m, up 23% on pcp
- USA revenue grew 28% to $23.2m, constituting 48% of total revenue
- Bubs achieved a gross margin of 50% compared to 49% in the pcp
- Positive operating cash flow of $3.9m in Q2 FY25
- Bubs reaffirmed FY25 outlook guidance of $102m revenue
- Reduction in operating expenses as a percentage of revenue to 52% from 68%
- Successful implementation of pack size changes and a reduction in SKU count by 20%
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Urbanise.Com Limited (UBN) ORDINARY FULLY PAID |
Information Technology |
$57 |
1H2025 Results Announcement
|
28 Feb 2025 8:56AM |
$0.510 |
$0.720 |
risen by
41.18%
|
|
UBN - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY2025 licence revenue of $5.9m up 2%
- Total revenue of $6.3m, increased by $35k
- Annualised Recurring Revenue (ARR) decreased by 3% to $11.3m
- EBITDA loss improved by 41.2% to $0.9m
- Average monthly cash generated was $139k
- Closing cash balance increased to $2.7m with no material debt
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Donaco International Limited (DNA) ORDINARY FULLY PAID |
Consumer Discretionary |
- |
1H FY25 Results Summary
|
28 Feb 2025 8:56AM |
$0.030 |
$0.045 |
risen by
50%
|
|
DNA - Price-sensitive ASX Announcement
Full Release
Key Points
- Group net revenue of A$21.83 million represents a 12.2% increase compared to 1H FY24.
- EBITDA increased by 17.0% to A$11.39 million.
- Net profit after tax rose to A$7.77 million, a 36.3% increase from the previous year.
- DNA Star Vegas reported net revenue of A$14.08 million with an EBITDA of A$8.10 million.
- Aristo International Hotel's revenue increased by 27.3% to A$7.76 million, with EBITDA up 39.9%.
- The company had a strong cash position of A$36.26 million as of 31 December 2024.
- Donaco faces regulatory challenges in Thailand which may impact operations.
- Legal proceedings related to tax issues in Vietnam are ongoing, with potential financial implications.
- The company remains optimistic about future growth opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$304 |
Notification of cessation of securities - PBH
|
28 Feb 2025 8:55AM |
$1.110 |
$0.875 |
fallen by
21.17%
|
|
| Arcadium Lithium Plc (LTM) ORDINARY FULLY PAID |
Materials |
- |
Arcadium Lithium Q4 2024 Earnings Form 8-K
|
28 Feb 2025 8:55AM |
$9.250 |
$9.330 |
risen by
0.86%
|
|
LTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Q4 2024 revenue was $289 million.
- Annual revenue for 2024 reached $1,007.8 million.
- GAAP net loss in Q4 was $14.2 million.
- Attributable GAAP net income for the year was $103.2 million.
- Sales volumes increased by 56% in Q4 but remained flat year-over-year.
- Average realized pricing in Q4 was $15,700 per product metric ton.
- Arcadium Lithium is set to be acquired by Rio Tinto for $5.85 per share.
- The transaction with Rio Tinto is expected to close on March 6, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Australia Limited (FGX) ORDINARY FULLY PAID |
Financials |
$588 |
Corporate Governance Statement
|
28 Feb 2025 8:55AM |
$1.270 |
$1.430 |
risen by
12.60%
|
|
| Resource Development Group Limited (RDG) ORDINARY FULLY PAID |
Industrials |
- |
RDG HY25 Investor Update
|
28 Feb 2025 8:54AM |
$0.015 |
$0.008 |
fallen by
46.67%
|
|
| Bisalloy Steel Group Limited (BIS) ORDINARY FULLY PAID |
Materials |
$289 |
1H25 Results for Announcements to Market & Half Year Report
|
28 Feb 2025 8:54AM |
$3.200 |
$6.010 |
risen by
87.81%
|
|
BIS - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue decreased by 7.5% to $70.9 million.
- Profit after tax increased by 5.2% to $8.73 million.
- Profit before tax rose by 5.9% to $12.8 million.
- Operating EBITDA improved by 4.6% to $14.66 million.
- Interim dividend of 8.0 cents per share declared.
- Sales and margins improved in the overseas markets of Thailand and Indonesia.
- Protection Steel volumes down 12.5% due to port industrial action.
- Overall cash inflow of $1.84 million compared to an outflow of $1.00 million the previous year.
- Inventory levels increased by 17.9% reflecting changes in order phasing.
- The company aims to complete significant contracts in the second half of FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$300 |
Update - Notification of buy-back - AMH
|
28 Feb 2025 8:54AM |
$1.150 |
$0.950 |
fallen by
17.39%
|
|
| Urbanise.Com Limited (UBN) ORDINARY FULLY PAID |
Information Technology |
$57 |
Appendix 4D and 1H25 Financial Report
|
28 Feb 2025 8:54AM |
$0.510 |
$0.720 |
risen by
41.18%
|
|
UBN - Price-sensitive ASX Announcement
Full Release
Key Points
- Urbanise.com Limited announced its financial results for the half-year ended 31 December 2024.
- Revenue increased slightly to $6.3 million, up 0.6% from the previous year.
- The company experienced a net loss of $1.7 million, a notable increase from the prior year's loss.
- Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) improved significantly compared to the previous period.
- Urbanise secured 19 new contracts adding to its annual recurring revenue.
- The company introduced a new share appreciation rights scheme to align management incentives with long-term shareholder value.
- The Strata segment faced revenue reallocation challenges that slightly affected reported revenue.
- The company is focused on enhancing its platform and establishing banking service partnerships.
- The report indicates a cautious outlook regarding going concern due to current liabilities exceeding current assets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bubs Australia Limited (BUB) ORDINARY FULLY PAID |
Consumer Staple |
$112 |
Bubs Australia - Half Year Report and Appendix 4D
|
28 Feb 2025 8:53AM |
$0.145 |
$0.125 |
fallen by
13.79%
|
|
BUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 23% to $48.5 million.
- Profit after tax turned positive at $3.55 million.
- Strong growth driven by markets in the USA, China, and rest of the world.
- Focus on premium infant formula and successful U.S. FDA regulatory initiatives.
- Gross margin improved to 50% due to effective cost management.
- Operating expenses increased but managed effectively.
- Bubs continues to dominate the goat infant milk formula market in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Avecho Biotechnology Limited (AVE) ORDINARY FULLY PAID |
Health Care |
$35 |
Trading Halt
|
28 Feb 2025 8:53AM |
$0.007 |
$0.010 |
risen by
35.71%
|
|
AVE - Price-sensitive ASX Announcement
Full Release
Key Points
- Avecho Biotechnology Limited requests a trading halt.
- The halt is pending the release of an announcement.
- The announcement pertains to an exclusive license and development agreement.
- The halt will last until 3 March 2025 or until the announcement is made.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Synertec Corporation Limited (SOP) ORDINARY FULLY PAID |
Industrials |
$13 |
Appendix 4D - Interim Financial Report - FY25 H1
|
28 Feb 2025 8:52AM |
$0.045 |
$0.025 |
fallen by
44.44%
|
|
SOP - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased from $9.1 million to $8.5 million.
- Net loss after tax increased to $4.25 million.
- Engineering division remains profitable with positive cash flow.
- No dividends declared for the period.
- Powerhouse system received increased interest.
- Strategic initiatives for operational efficiency and market expansion are in progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scalare Partners Holdings Limited (SCP) ORDINARY FULLY PAID |
Consumer Staple |
$7 |
Appendix 4D and Financial Report 31 Dec 2024
|
28 Feb 2025 8:52AM |
$0.160 |
$0.080 |
fallen by
50%
|
|
SCP - Price-sensitive ASX Announcement
Full Release
Key Points
- Scalare Partners Holdings Limited was formed after acquiring Scalare Partners Pty Limited.
- The company reported a total income of $1.54 million for the half-year ended December 31, 2024.
- Service revenue increased by 94% to $1.17 million due to program expansions.
- The company recorded a loss of $1.3 million attributed to listing expenses.
- New initiatives are focused on supporting early-stage companies and enhancing advisory services.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$166 |
Appendix 4D and Interim Financial Report
|
28 Feb 2025 8:50AM |
$0.430 |
$0.575 |
risen by
33.72%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Company reported a half-year operating loss of A$7.74 million.
- R327 demonstrated significant efficacy against Acinetobacter baumannii.
- Raised A$12.4 million through institutional placements and a share purchase plan.
- Received US$2 million grant from the US Department of Defence for R327G.
- Initiated Phase II clinical trials for R327G targeting diabetic foot infections.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| McPherson's Limited (MCP) ORDINARY FULLY PAID |
Consumer Staple |
$28 |
Board Update
|
28 Feb 2025 8:50AM |
$0.255 |
$0.195 |
fallen by
23.53%
|
|
| Donaco International Limited (DNA) ORDINARY FULLY PAID |
Consumer Discretionary |
- |
Appendix 4D and Half Year Financial Report
|
28 Feb 2025 8:49AM |
$0.030 |
$0.045 |
risen by
50%
|
|
DNA - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit for half-year ended 31 December 2024 was $7,769,143.
- Profit increased from $5,701,993 in the previous year.
- Donaco operates hotels and casinos in Vietnam and Cambodia.
- The report includes financial performance details.
- Directors express confidence in meeting financial obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
